Wegovy leads to ‘substantial’ BMI decrease for children
NATIONAL HARBOR, Md. — Once-weekly injectable semaglutide reduced BMI for children with obesity as young as age 6 years, according to data from the phase 3 STEP Young trial presented at ObesityWeek.
As Healio previously reported, semaglutide (Wegovy, Novo Nordisk) was approved by the FDA for adolescents aged 12 to 17 years in December 2022. Martin Wabitsch, MD, PhD, professor of pediatrics at Ulm University Medical Center in Germany, said there are no GLP-1 receptor agonists approved in the U.S. for children younger than age 12 years, and early treatment of obesity could help children avoid